Related Experiment Video
Updated: Mar 31, 2026
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?
1The Ohio State James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio, USA Richard.Goldberg@osumc.edu.
Abstract:
Remarkable strides have been made in the past 10-15 years in identifying the molecular events that drive cancer. With an enormous amount of new data, including those from The Cancer Genome Atlas Project, therapies are increasingly being developed and tested in clinical trials specifically designed to target some of these molecular events. Often, molecular signatures have become more important than the histologic features in making treatment choices. The success rate of these therapies depends on many factors but, perhaps most importantly, on patient selection according to the genetic analysis results of their individual tumors.
Insights
Recent cancer research identifies molecular drivers, leading to targeted therapies. Patient selection based on tumor genetic analysis is crucial for treatment success.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Significant advancements in identifying cancer-driving molecular events over the last 10-15 years.
- The Cancer Genome Atlas Project has generated vast amounts of data fueling new research.
- Molecular signatures are increasingly guiding cancer treatment decisions over traditional histologic features.
Purpose of the Study:
- To highlight the shift towards molecularly targeted cancer therapies.
- To emphasize the importance of genetic analysis in patient selection for clinical trials.
- To underscore the role of molecular signatures in modern oncology.
Main Methods:
- Review of recent molecular profiling data and clinical trial designs.
- Analysis of the impact of The Cancer Genome Atlas Project findings.
- Correlation of molecular signatures with treatment outcomes.
Main Results:
- Development and testing of novel therapies targeting specific molecular events in cancer.
- Increased reliance on molecular signatures compared to histologic features for treatment selection.
- Demonstration that patient selection via tumor genetic analysis is a key factor for therapy success.
Conclusions:
- Molecularly targeted therapies represent a paradigm shift in cancer treatment.
- Accurate patient stratification based on individual tumor genetics is essential for optimizing therapeutic efficacy.
- Continued research in cancer genomics is vital for advancing precision oncology.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenomics: Identification of New Drug Targets
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...